Evogene (EVGN) EPS (Basic) (2012 - 2026)

Evogene (EVGN) posted EPS (Basic) of -$0.0 for Q1 2026, up 99.91% sequentially from -$0.67 in Q4 2025, and down 58.4% YoY from -$0.0 in Q1 2025.

Evogene (EVGN) EPS (Basic) (2012 - 2026) Analysis & Trends

Evogene has reported EPS (Basic) for 15 years, with the latest figure at -$0.0 in Q1 2026.

Quarterly EPS (Basic) fell 58.4% year-over-year to -$0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.0 (down 87.93% YoY) and the FY2025 annual result came in at -$1.08, up 62.76% from the prior year.
EPS (Basic) grew to -$0.0 in Q1 2026 per EVGN's latest filing, from -$0.67 in the prior quarter.
Over five years, EPS (Basic) peaked at $2.14 in Q2 2022 and troughed at -$1.44 in Q4 2023.
A 5-year average of $0.09 and a median of -$0.0 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) surged 237.16% in 2022, then sank 999.61% in 2025.
Over 5 years, EPS (Basic) stood at -$0.73 in 2022, then sank by 98.61% to -$1.44 in 2023, then jumped by 105.19% to $0.07 in 2024, then tumbled by 999.61% to -$0.67 in 2025, then jumped by 99.91% to -$0.0 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.0, -$0.67, and $0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	12.62
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	7.59
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.23
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-0.72
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.18
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	-0.75

Download Data